A study published by the Centers for Disease Control and Prevention focusing on vaccination coverage of teenagers from 13 to 17 presents a good-news/bad-news scenario.
Good news: Adolescent vaccination rates for meningococcus (MenACWY, which protects against meningococcal meningitis), tetanus/diptheria/acellular pertussis (Tdap) and human papillomavirus (HPV), all increased from 2009 and 2010. Bad news: HPV vaccination rates lagged the other two, and less than one-third of the subjects completed the three-shot series.
Vaccinating against HPV protects girls from developing cervical cancer later in life and can protect boys from genital warts and anal cancer. But the shot has to be given before sexual activity begins.
The CDC survey has collected provider-verified vaccination data since 2006 in a random telephone survey of parents or caregivers, verified by records from health-care providers. The latest survey found that almost two-thirds of respondents had received MenACWY, slightly more than two-thirds had received the Tdap and nearly half of respondents received one the recommended three doses for HPV vaccine.
From 2009 to 2010, among girls who received the three HPV doses, coverage increased by 5 in 100, which was considerably less than those observed for the Tdap (13 in 100) and meningitis (9 in 100) vaccines.
There were notable geographic differences in who got the vaccines, with states in the southeast lagging other regions.
Melinda Wharton, M.D., M.P.H. and deputy director of the CDC's National Center for Immunization and Respiratory Diseases said, "Far too few U.S. girls are getting the HPV vaccine. We can do better at this — we've got in our possession a very powerful tool: a vaccine that prevents cancer," she said. "If we all take actions to protect girls starting today, we'll have generations of women who will never be diagnosed with cervical cancer."
One manufacturer’s HPV vaccine also is recommended for adolescent males to prevent four common HPV strains that cause genital warts and anal cancer.
Wharton told Medscape that several factors might explain the disparity in rates between HPV vaccination and the other two. Adherence is a lot easier for a single-dose vaccine than for one that requires three shots. And many parents believe that girls are too young at the recommended age (11 or 12) to receive the vaccine.
There isn’t really an answer to the first impediment, and the CDC recommends a two-dose series for MenACWY. As for the second impediment, as Wharton points out, the vaccine doesn’t work “unless it is given prior to the onset of sexual activity, and that's why we recommend it so young."
"Even if we know our children very well, we don't know when they are going to be first sexually active," Wharton said. "It's also possible that most parents are not going to be as concerned about [the young age at first dose] as providers think they might," she said. "If a provider makes a strong recommendation for this vaccine ... it may be that parents won't have many questions about it."
Your pediatrician doesn’t schedule vaccinations according to personal habits or family dynamics. It’s about preventing disease the most effective way possible. Science doesn’t judge; it analyzes.